AXSM vs PEN: Which Stock Is the Better Buy?
Axsome Therapeutics, Inc. and Penumbra, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — AXSM vs PEN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Axsome Therapeutics, Inc. (AXSM) | Penumbra, Inc. (PEN) | |
|---|---|---|
| Market cap | $13.0B | $12.6B |
| Revenue (latest FY) | $638.50M | $1.40B |
| Net income (latest FY) | $-183.17M | $177.69M |
| Revenue growth (5y CAGR) | — | 20.2% |
| Net margin | -28.7% | 12.7% |
| Return on equity | -207.5% | 12.4% |
| P/E ratio | — | 73.8 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 8 |
| Positive free cash flow | No | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full AXSM vs PEN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open AXSM's full financials → Open PEN's full financials →More comparisons
Frequently asked questions
Which is bigger, AXSM or PEN?
Axsome Therapeutics, Inc. is larger by market capitalization — $13.0B versus $12.6B.
Which grows faster, AXSM or PEN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
AXSM fundamentals → · PEN fundamentals → · All 1,500+ companies → · Free screener →